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Abstract: 
Systemic Lupus Erythematosus is a complex autoimmune rheumatic 
disease with multiple presentations, whose management presents many 
challenges. Many disease modifying or immunosuppressive drugs have 
been used with limited success, especially in patients with more severe 
disease activity. Belimumab is the first drug to be approved specifically for 
the treatment of Systemic Lupus Erythematosus in more than 50 years. By 
blocking the B-cell activating factor, it interferes in B-cell differentiation 
and survival. Here we consider the results of the clinical trials that led to 
its approval, as well as the post-hoc analyses, follow-up studies and the 
current trials.  
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1. Introduction 
In 2016, the National Institute for Health and Care Excellence (NICE) 
approved the use of belimumab for the treatment of autoantibody-
positive Systemic Lupus Erythematosus (SLE) [NICE, 2016]. It is timely to 
review the prospects for belimumab in the United Kingdom and 
worldwide.  
In 2011, belimumab became the first drug in over to be approved by the 
Federal Drug Administration (FDA) in the United States of America (USA) 
for the treatment of SLE. It is available in the USA for autoantibody 
positive lupus patients with active, skin or joint disease who have 
inadequate response to standard therapy. It is not, however, approved for 
the treatment of renal disease or severe central nervous system (CNS) 
involvement in SLE [US FDA., 2012]. 
It interesting to consider what the two clinical trials that led to its approval 
actually found [Furie et al., 2011, Navarra et al., 2011]. We will also review 
the follow up studies. 
 
2. Clinical trials 
Belimumab is a recombinant, fully human IgG1λ mAb which binds to 
soluble B-lymphocyte stimulator (BAFF) [Baker et al., 2003]. Given that 
BAFF inhibits B-cell apoptosis, stimulates the differentiation of B cells into 
immunoglobulin-producing cells [Do et al., 2000] and BAFF serum levels 
correlate with disease activity [Petri et al., 2008], it was hypothesized that 
it might be a target in SLE treatment.  
A phase I trial of belimumab in 70 SLE patients with stable disease for two 
months indicated an abnormal rate of adverse events, but there was a 
significant reduction in percentages of CD20+ B cells and anti-dsDNA 
autoantibody titres after one or two doses of belimumab, without any 
changes in disease activity [Furie et al., 2008]. A 52-week-phase II trial 
included 449 SLE patients with active disease. Belimumab was 
administered to 336 and placebo to 113 patients. The inclusion criteria 
required a Safety of Oestrogen in Lupus Erythematosus National 
Assessment SLE Disease Activity Index (SELENA-SLEDAI) score ≥4, history 
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of measurable antibodies (not necessarily present at screening) and a 
stable therapeutic regimen for ≥60 days. Patients with active lupus 
nephritis or CNS disease were excluded. Patients were randomized to 
receive 1, 4, or 10 mg/kg of belimumab or placebo on days 0, 14, 28, and 
subsequently every 28 days for 52 weeks plus standard of care [Wallace et 
al., 2009].  
The primary clinical endpoints (change in SELENA-SLEDAI score at week 24 
and time to first flare) were not met, as the mean percent changes in 
SELENA-SLEDAI were -19.5% for the belimumab groups versus -17.2% for 
the placebo group at 24 weeks, and -27.2% versus -20.6% at 52 weeks. 
Similarly, there were no differences between the four groups in the rate of 
flares (mild/moderate or severe) or time to first flare over 52 weeks, but 
time to first flare starting at week 24 through week 52 showed a median 
time of 154 days in the belimumab groups and 108 days in the placebo 
group (p=0.0361), suggesting that belimumab might stabilize the disease. 
However, almost 30% of the patients were ANA negative, which lead to 
concerns about the veracity of the diagnosis. But, we have reported that 
in a 10-year period 17% of strongly ANA positive lupus patients become 
ANA negative [Acosta-Mérida et al., 2013]. A subgroup analysis in the 
Belimumab study demonstrated that serologically active patients ANA 
≥1:80 or levels of anti-dsDNA autoantibody ≥30 IU/mL) treated with 
belimumab had a significantly greater reduction in SELENA-SLEDAI scores 
from baseline to week 52 [Wallace et al., 2009]. 
Based on the phase II trial results, a new SLE responder index (SRI) was 
developed for use in clinical trials. This  tries to capture an improvement in 
disease activity without worsening of the overall condition or the 
development of significant disease activity in new organ systems. A 
responder is defined as a ≥4-point reduction in SELENA-SLEDAI score, no 
new British Isles Lupus Assessment Group (BILAG) A or no >1 new BILAG B 
domain score and no deterioration from baseline in the Physician’s Global 
Assessment (PGA) by ≥0.3 points [Furie et al., 2009].  
Two phase III trials were designed: BLISS-52 and BLISS-76 were conducted. 
The BLISS-52 trial recruited 865 patients from South America, Asia and 
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Eastern Europe [Navarra et al., 2011]. BLISS-76 assessed 819 patients in 
North America, Europe and Israel [Furie et al., 2011], leading to two 
different ethnic origin distributions. They had a similar design. The 
inclusion criteria were SLE patients aged ≥18 years, SELENA-SLEDAI ≥6 and 
stable treatment regimen for at least 30 days. Both trials included only 
serologically active SLE patients [Furie et al., 2011, Navarra et al., 2011]. 
The exclusion criteria were severe active lupus nephritis or CNS 
involvement; pregnancy; previous treatment with any B-lymphocyte-
targeted drug, intravenous cyclophosphamide in the previous 6 months, 
and IVIg or prednisone >100 mg/day within 3 months [Furie et al., 2011, 
Navarra et al., 2011]. The patients were randomized in a 1:1:1 ratio to 
receive 1 mg/kg belimumab, 10 mg/kg belimumab, or placebo 
intravenously on days 0, 14, and 28 and then every 28 days until 48 weeks 
in the BLISS-52 trial [Navarra et al., 2011] and for 72 weeks in the BLISS-76 
trial [Furie et al., 2011]. The standard of care regimen and limitations on 
steroid use are described elsewhere. [Furie et al., 2011]. 
The primary endpoint in both trials was the SRI response rate at week 52 
[Furie et al., 2011, Navarra et al., 2011]. The secondary endpoints were 
the percentage of patients with a 4-point reduction from baseline in 
SELENA–SLEDAI score at week 52, change in PGA score at week 24, change 
in Short Form 36 version 2 (SF36) at week 24 and percentage of patients in 
which the mean prednisone dose was decreased 25% from baseline to 7.5 
mg/day or less during weeks 40–52 [Furie et al., 2011, Navarra et al., 
2011]. In the BLISS-76 trial, SRI response rate at week 76 was also a 
secondary endpoint [Furie et al., 2011]. 
In the BLISS-52 trial, belimumab resulted in a significantly higher response 
rate (1 mg/kg – 148; 51%; p=0·0129 and 10 mg/kg - 167; 58%; p=0·0006) 
compared to placebo (125; 44%) at week 52 as assessed by SRI. This 
revealed a dose-response pattern, as belimumab 10 mg/kg had a 
significantly greater response than placebo in all three SRI components, 
though belimumab 1 mg/kg showed a greater response than placebo in 
SELENA-SLEDAI and PGA [Navarra et al., 2011]. 
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In the BLISS-76 trial, there were more SRI responders in the 10 mg/kg 
belimumab group than in the placebo group (43.2% versus 33.5%; 
p=0.017) at 52 weeks. However, the percentage of SRI responders in the 1 
mg/kg belimumab group (40.6%), while numerically greater than that in 
the placebo group, was not statistically significant (p=0.089). Similarly, at 
week 76 the SRI response rates were numerically greater in the 
belimumab groups than in the placebo group, but not significant [Furie et 
al., 2011]. 
Significantly greater and sustained reductions were noted in anti-dsDNA 
antibody levels in the belimumab groups in both trials when compared to 
placebo [Furie et al., 2011, Navarra et al., 2011], 
In the BLISS-52 trial, the patients with baseline prednisone doses >7.5 
mg/day showed that sustained dose reduction (≥12 weeks until week 52) 
was more likely with belimumab 1 mg/kg and 10 mg/kg than with placebo 
[Navarra et al., 2011]. In the BLISS-72 trial, more patients in the 
belimumab groups were able to reduce corticosteroids by 25% and to 7.5 
mg/day between weeks 40 and 52 compared with patients receiving 
placebo, but this was not significant [Furie et al., 2011]. 
The rates of adverse effects were similar between all three groups in both 
trials [Furie et al., 2011, Navarra et al., 2011]. 
2.1. Post-Hoc Analyses 
Several studies pooled the data from both phase III trials in post-hoc 
analyses to detect the treatment effects in more detail, but the BLISS trials 
were not powered to assess these parameters. One of the studies 
compared the changes in different measures at 52 weeks between SRI 
responders (n=761) and non-responders (n=923). Responders were more 
likely to have higher disease activity, less serological activity (based on 
anti-dsDNA titre - p<0.001; percentage of patients with C3 or C4 levels less 
than the lower limits of normal - p<0.001 and p<0.0001, respectively), and 
to have received a corticosteroid dose >7.5 mg/d (p<0.01), but not an 
immunosuppressant (p<0.0001) [Furie et al., 2014]. More responders than 
non-responders achieved a ≥4 point reduction in SELENA-SLEDAI score 
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(3.8% of non-responders versus 100% of responders; p<0.001), while a 
reduction of ≥7 occurred in 40.3% of responders versus 1.3% of non-
responders [Furie et al., 2014]. 
Another study assessed which factors were related to a greater response 
to belimumab. In the univariate analysis, patients with a higher baseline 
disease activity (SELENA–SLEDAI ≥10, low complement levels, raised anti-
dsDNA autoantibody levels or treatment with corticosteroids) had a 
greater response versus standard therapy alone, especially the belimumab 
10 mg/kg group. In the multivariate analysis, the serologically active 
subgroup was more difficult to treat with standard therapy (SRI rate of 
32% versus 39% in the overall population and 44% in the SELENA–SLEDAI 
≥10 subgroup) and belimumab treatment led to significantly greater SRI 
response rates when compared to placebo at 52 weeks (SRI rate 31.7% 
with placebo; 41.5%  with belimumab 1 mg/kg (p=0.002); and 51.5% with 
belimumab 10 mg/kg (p<0.001)), even when complement and anti-dsDNA 
autoantibodies changes were excluded from the SRI (28.9% with placebo; 
38.7% with belimumab 1 mg/kg (p= 0.001) and 46.2% with belimumab 10 
mg/kg (p<0.001)) [Van Vollenhoven et al., 2012]. 
More patients treated with belimumab showed a 4-point or greater 
reduction in the SELENA–SLEDAI score at week 52 when compared to 
placebo (40.7% with placebo; 48.1% with belimumab 1 mg/kg (p=0.006); 
52.6% with belimumab 10 mg/kg (p<0.001)) and the proportions with no 
new BILAG A or no more than one new B score at week 52 were 76.7% 
(p=0.005) and 75.5% (p=0.02) with belimumab 1 and 10 mg/kg, 
respectively, versus 69.4% in the placebo group. At 52 weeks, there was a 
significantly higher number of patients in both belimumab groups with 
improvement in the musculoskeletal and mucocutaneous BILAG domains. 
Similarly, significantly more patients in the belimumab groups had 
improvements in the musculoskeletal (1 mg/kg), mucocutaneous (10 
mg/kg), and immunological (1 and 10 mg/kg) domains, as assessed by 
SELENA-SLEDAI. The changes in adjusted mean SELENA–SLEDAI scores 
over 52 weeks were significantly greater with belimumab 1 and 10 mg/kg 
for the musculoskeletal and immunological domains over 52 weeks and 
for the immunological domain from weeks 24 to 52. When removing the 
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contribution of these three organ domains or both the musculoskeletal 
and mucocutaneous domains to SELENA–SLEDAI, the treatment effect 
with belimumab remained. There were significantly fewer patients treated 
with belimumab than placebo who had worsening in the SELENA-SLEDAI 
immunological, haematological and renal domains, or BILAG 
haematological domain (p<0.05) when these specific organ domains were 
not involved at baseline [Manzi et al., 2012]. 
Although the BLISS trials were not designed to assess the effects of 
belimumab in renal disease, one post-hoc analysis assessed whether the 
patients with stable renal involvement had any additional benefit from 
belimumab. At week 52, a higher proportion of patients with SELENA-
SLEDAI renal involvement at baseline and treated with belimumab had 
renal improvement, including reductions in haematuria and proteinuria. 
Of 267 patients with SELENA-SLEDAI renal involvement, a greater 
percentage of the subset of serologically active patients (n =182) had renal 
organ system and item improvements with belimumab 10mg/kg vs. 
standard therapy alone, but it was not statistically significant. Similarly, in 
patients with renal involvement who were treated with mycophenolate 
mofetil (MMF) at baseline, there was a SELENA-SLEDAI renal 
improvement: 27.8% in the placebo group, 52.6% in belimumab 1 mg/kg, 
63.2% in belimumab 10 mg/kg which was statistically significant (p= 0.03). 
There was also a BILAG renal improvement (20.0%, 32.4%, and 30.6% in 
the placebo, and belimumab 1 and 10 mg/kg groups, respectively), but 
this was not statistically significant [Dooley et al., 2013]. 
There was a lower rate of renal flares in patients receiving belimumab. In 
the subgroup of patients receiving MMF at baseline, the rates of renal 
flares during the 52 weeks were 4.9%, 4.9%, and 1.5% with placebo, and 
belimumab 1 and 10 mg/kg, respectively (not statistical significant) 
[Dooley et al., 2013] 
Significantly more pooled patients treated with belimumab converted to 
seronegative for anti-dsDNA (both doses of belimumab), anti-Sm (10 
mg/kg), anti-ribosomal P (10 mg/kg), and IgG anti-cardiolipin (both doses) 
autoantibodies by week 52. By week 8, there was a significantly lower 
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anti-dsDNA autoantibody level in both belimumab groups compared to 
placebo (p<0.001). In patients with low complement levels at baseline, 
significant and sustained increases were observed with belimumab by 
week 4 compared to placebo (in the 1 mg/kg group - p<0.05; in the 10 
mg/kg group – p<0.001). Plasma cells decreased in a dose-dependent 
manner with belimumab [Furie et al., 2014], which is clinically relevant as 
it has been shown that the number and frequency of CD27(high) plasma 
cells correlate with SLE disease activity and with anti-dsDNA 
autoantibodies titre [Jacobi et al., 2003]. In contrast, seroconversion to 
anti-dsDNA positivity was infrequent and occurred significantly more 
often in patients receiving placebo than in those receiving 10 mg/kg of 
belimumab (p=0.02) [Stohl et al., 2012]. When comparing SRI responders 
with non-responders, median anti-dsDNA autoantibody levels were lower 
in SRI responders than in non-responders at week 52 (−34.2% vs −26.1%; 
p=0.01), normalisation of anti-dsDNA levels occurred in more responders 
(14.4% vs 10.8%; p=0.10) and when hypocomplementaemia was present 
at baseline, a greater median per cent increase was observed in 
responders (C3: 14.5% vs 9.0% - p=0.001; C4: 40.0% vs 28.6% - p=0.003) 
[Furie et al., 2014].  
In terms of health-related quality of life scores, one of the analyses found 
significantly greater improvements in Physical Component Summary, SF-
36 vitality domain, and Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-Fatigue) scores in both belimumab groups at week 52 
[Strand et al., 2014]. For SRI responders, mean improvements in SF-36 
physical component summary (PCS) and mental component summary 
(MCS) scores were greater when compared to non-responders at week 52 
(4.9 vs 2.6 and 4.4 vs 1.7, respectively; p<0.001) and exceeded minimum 
clinically important differences (MCID), defined as a 2.5 points difference 
from baseline; a higher percentage of responders also showed 
improvements ≥MCID, both in PCS (59% vs 49%) and in MCS (56% vs 44%). 
Sustainable improvement in SF-36 scores throughout the trial were not 
observed [Furie et al., 2014]. 
A total of 86% percent of the pooled patients received corticosteroid 
therapy and the mean dose (prednisone equivalent) was 12.5 mg/day. 
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While the overall exposure to all corticosteroids increased on average in 
all treatment groups from baseline to 52 weeks, the overall mean 
cumulative change in corticosteroid dose was 531 mg in the belimumab 
10 mg/kg group versus 916 mg in the placebo group (p<0.0001) and the 
mean overall change in daily corticosteroid dose was 1.5 mg with 
belimumab 10 mg/kg and 2.5 mg with placebo (p<0.0001). Similarly, only 
22.6% of patients treated with belimumab 10 mg/kg had an increase in 
corticosteroids over 52 weeks versus 35.0% of patients on placebo. A total 
of 37% of patients had a decrease in corticosteroid dose while on 
belimumab 10 mg/kg versus 29.7% of patients on placebo [Van 
Vollenhoven et al., 2016]. When comparing SRI responders with non-
responders at week 52, of the patients treated with prednisone >7.5 
mg/day at baseline (62% of responders; 55% of non-responders), it was 
observed that more responders than non-responders had dose reductions 
≥25% to <7.5 mg/day (25.5% vs 16.4%; p<0.001). There were fewer 
responders who had their prednisone dose increased to >7.5 mg/day at 
week 52 from ≤7.5mg/day at baseline (4.1% vs 21.3%; p<0.001) [Furie et 
al., 2014]. 
2.2.  Safety Considerations in the BLISS trials 
The safety profile was analysed on the pooled data from the phase II and 
III trials (n=1458 patients). The most common cause of withdrawal was 
adverse events, which did not vary significantly between the 3 groups. 
These included renal disorders (1.2%, 0.9%, 0%, and 1.2% with placebo, 
and belimumab 1, 4, and 10 mg/kg, respectively), infections (1.2%, 0.7%, 
0.9%, and 0.6%), neurologic disorders (0.6%, 0.7%, 0%, and 1.0%), and skin 
disorders (0.9%, 0.4%, 0.9%, and 0.7%). The rate of serious infections was 
also similar across treatment groups [Wallace et al., 2013]. 
In the BLISS-76 trial, patients were assessed for changes in pre-existing 
antigen-specific antibodies and response to vaccination during the study. 
Despite the small number of patients, no difference was found in anti-
tetanus toxoid IgG levels between the placebo, belimumab 1 mg/kg and 
10 mg/kg groups. There was an increase in antibody levels to the tested 
antigens after anti-pneumococcal vaccination was administered, in both 
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placebo and belimumab groups, but these were not consistent. Even 
healthy subjects may not mount a response to all serotypes. In total, 89 
patients received influenza vaccine during the study and the antibodies to 
all antigens increased in all groups [Chatham et al., 2012]. 
The data relating to pregnancy are sparse. In the phase II and III clinical 
trials, there were 54 pregnancies on belimumab, of which 21 resulted in 
live births, 13 ended in foetal loss, 10 were electively terminated, 6 were 
ongoing, and 4 had an unknown outcome. Two live births on belimumab 
had congenital abnormalities. Six pregnancies occurred on placebo and 3 
ended in foetal loss and 3 were electively terminated [Wallace et al., 
2013]. 
In the pooled data of the phase II and III clinical trials, during the blinded 
period, there were 14 deaths (3 on placebo, 5 on belimumab 1 mg/kg, 
none on 4 mg/kg, and six on 10 mg/kg), with a mortality rate of 0.43 (95% 
CI 0.09– 1.27; 692 patient-years) with placebo and 0.73 (95% CI 0.36–1.30; 
1516 patient-years) with belimumab (1, 4, and 10 mg/kg dosages 
combined) [Wallace et al., 2013].  
3. Long term follow up 
3.1. Clinical Efficacy 
The initial post-marketing experience was described in small observational 
studies. One study included 115 patients who received belimumab for at 
least 3 months, of whom 79 received it for at least 6 months. The other 
study included 68 patients who had received one previous belimumab 
infusion. The most common clinical manifestations in these two studies 
were arthritis (73.5% and 52%, respectively), mucocutaneous involvement 
(51.0% and 19%), and serositis (17.2% and 8%). Clinical response was 
defined by a ≥ 50% reduction in the investigator’s impression in addition 
to no worsening in other organ systems in the first study. Less than half of 
the patients responded in either or both arthritis and rash at 3 months 
and <60% clinically responded in arthritis, rash and/or nephritis at 6 
months. Belimumab was discontinued in 13.2% of patients for various 
reasons. In the second study, PGA, SELENA-SLEDAI score and prednisone 
dose were compared between baseline, 6 and 12 months of follow-up. 
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PGA and SELENA-SLEDAI score decreased during those 12 months, from 
1.35 to 0.78 and from 4.40 to 2.30, respectively. However, during this 
period, 18 patients discontinued the treatment and the corticosteroid 
dosage remained stable (17.8 mg/day at baseline and 16.0 mg/day at 12 
months) [Askanase et al., 2014]. These results are not impressive. 
Another observational non-controlled study (the OBSErve study) reviewed 
patients who had received ≥8 infusions of belimumab in a clinical setting 
(excluding those who took part in clinical trials) to evaluate clinical 
response at the end of each 6-month period for 24 months [Collins et al., 
2016]. As previously reported [Askanase et al., 2014], the primary 
outcome was physician’s impression of change, defined by a physician 
described response of 20%, 50%, and 80% improvement for each 6-month 
period. Of 501 patients, 112 were lost to follow up and 112 discontinued 
treatment, due to patient request (n=45), lack of medication efficacy 
(n=33) and adverse effects (n=14), usually sepsis or depression. At 
baseline, 2.2% of patients had mild, 77.6% moderate and 20.2% severe 
disease and the mean SELENA-SLEDAI score (n=122) was 12.4 [Collins et 
al., 2016].  The most commonly involved organ systems were 
musculoskeletal (76.9%), mucocutaneous (63.5%), constitutional (56.7%), 
immunological (54.0%) and haematological (35.3%). At month 6, the 
percentage of patients with moderate and severe disease reduced to 
47.7% and 2.4%, respectively, and at month 24 to 33.1% and 1.9%. 
Simultaneously, the mean SELENA-SLEDAI score showed a persistent 
reduction to 5.9 at month 6 and the percentage of anti-dsDNA-antibody 
positive patients also decreased (69.1% at baseline; 63.0% at month 6, 
50.9% at month 12 and 48.6% at month 24) [Collins et al., 2016]. As this 
was a non-controlled study, caution against an overoptimistic reaction is 
needed given the natural tendency of SLE patients’ disease activity to 
“wax and wane”. 
Patients who completed the phase II clinical trial could receive belimumab 
10 mg/kg in an open-label continuation study, which included 296 
patients and whose data relating to a total of 7 years of follow-up has 
already been published. By year 2, 57% of patients achieved an SRI 
response, which increased to 65% by Year 7. In the first year, the SRI 
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response was similar between seronegative and seropositive patients 
(44% vs 46%, respectively), becoming slightly lower in the second year 
when compared with seropositive patients (48% vs 57%, respectively). In 
years 3–7, the rate of SRI responders became similar again between both 
groups [Ginzler et al., 2014]. 
One further observational study with 195 patients on belimumab reported 
that 52% of patients showed an improvement in the clinical 
manifestations that had led to initiation of belimumab at 3 months, more 
specifically 61% of patients with arthritis, 43% of patients with rash, and 
78% of patients with renal manifestations. At 6 months, of 120 patients 
51% showed clinical response (46% of patients with arthritis, 52% of 
patients with rash, and 57% of patients with renal manifestations). 
Interestingly, black patients had a higher clinical response rate at 3 
months compared to non-black patients (82% vs 45%, p = 0.0001), and at 
6 months 67% out of 21 black patients responded to belimumab [Hui-
Yuen et al., 2015]. 
In the OBSErve study, of 251 patients with a ≥20% improvement in disease 
in the first 6 months, 99.2% reported no disease flare at months 12, 18 
and 24, and of 134 patients with a ≥50% improvement, 99.3% reported no 
worsening of disease later. Moreover, of 27 patients with SELENA-SLEDAI 
≥6 at baseline that reduced to <6 at month 6, none had an increase in 
SELENA-SLEDAI of >3 up to month 24 [Collins et al., 2016]. In patients who 
completed 7 years of treatment, the rate of any flares and severe flares 
declined from year 2 to 7, from 70.9% and 4.9% to 44.7% and 1.9%, 
respectively. The rate of flares was similar in the seronegative and 
seropositive patients [Ginzler et al., 2014]. However, patients were 
evaluated every 16 weeks, which might underestimate the occurrence of 
flares. Three clinical case reports described severe flares a year after 
discontinuation of belimumab in patients who had clinical improved 
during treatment, involving previously unaffected organs [Furer et al., 
2016]. 
Damage in the pooled patients from the 2 open-label continuation studies 
based on BLISS-52 and BLISS-76, at years 5-6 was evaluated. The mean 
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change in Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology Damage Index (SDI) from baseline to years 5–6 
was 0.2, while 343 out of 403 patients showed no change in SDI score, 46 
had an SDI increase of 1, 13 had an increase of 2, and 1 had an increase of 
3. Despite the absence of a control group, belimumab seemed to be 
associated with low rates of damage accrual [Bruce et al., 2016]. 
Corticosteroid usage decreased by 33% at Year 2 to 60% at Year 7 and the 
percentage of patient using corticosteroids declined from 73.9% at Year 2 
to 65.2% at Year 7 [Ginzler et al., 2014]. In the OBSErve study, 386 out of 
501 patients received steroids at baseline (mean daily dose of 19.9 mg). At 
month 6, 76.9% were on a reduced dose, 11.9% had no change, 9.1% 
stopped steroids, and 2.1% had a dose increase. The mean dose reduced 
to 8.4 mg/day. This trend continued from month 6 to month 24, with a 
mean dose of 6.1 mg/day. A gradual decrease in the proportion of 
patients on >7.5 mg/day was also observed (67.5% at baseline to 30.9% at 
month 6, 21.2% at month 12, 21.6% at month 18 and 18.4% at month 24) 
[Collins et al., 2016]. Another observational study did not show a 
significant decrease in the mean daily dosage at 6 months (from 12.2 
mg/day to 9.3 mg/day) [Hui-Yuen et al., 2015]. 
3.2. Safety in Long Term Follow-up 
No new concerns have emerged about adverse effects and mortality. In 
the 7-year-open-label continuation study, the most common adverse 
effects were mild-moderate infections in years 5–7, particularly upper 
respiratory tract infections. The serious adverse effects which affected ≥5 
patients in any year were cellulitis, transient ischemic attack, and 
pneumonia. Rates tended to decrease over time and the rate of serious 
and/or severe infections peaked during the first year [Ginzler et al., 2014]. 
Another study showed that >95% of patients had an adverse effect, with 
almost a third experiencing a severe adverse effect, but the incidence also 
decreased during the study from 10.8% (study year 0–1) to 5.6% (study 
year 5–6) [Bruce et al., 2016]. The most common adverse effects were 
infections/infestations (28.3%) and gastro-intestinal disorders (13.9%).  
Opportunistic infection was seen in 23 (2.3%) patients and herpes zoster 
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infection in 87 patients (8.7%) [Bruce et al., 2016]. 
Malignancies occurred at a similar rate to that expected in the general SLE 
population - 0.34/100 patient-years (95% CI 0.09–0.88) during the 4-year 
period (excluding non-melanoma skin-cancer) [Merrill et al., 2012] and of 
0.7/100 patient-years (95% CI 0.4–1.27) during the 7 year-period 
(including non-melanoma skin cancer). Seven non-melanoma skin cancers 
were reported on the 4-year period and 4 on the 5-7-year period [Ginzler 
et al., 2014]. 
The most common causes of discontinuation for clinical reasons over 7 
years were malignancies (9), infections (7), skin disorders (6), respiratory 
pathologies (5), and decreased IgG/hypogammaglobinaemia (4) [Ginzler et 
al., 2014]. 
During the 7 years of belimumab treatment, 7 deaths were reported 
(incidence rate of 0.4/100 patient-years). Five deaths occurred during the 
first 4 years and 2 occurred in year 7 [Ginzler et al., 2014].  In a study with 
pooled data from BLISS-52 and BLISS-76, 11 deaths were recorded during 
the 6-year study period and three additional deaths occurred after study 
exit. Causes of death included pneumonia, septic shock, pancreatitis, 
thrombocytopenia, cardiogenic shock, pulmonary haemorrhage, 
hypertensive heart disease, polypharmacy toxicity, stroke, intracranial 
haemorrhage and cardiac arrest [Bruce et al., 2016]. 
3.3. Cost effectiveness 
One-year of belimumab treatment is up to 20 times more expensive 
compared to immunosuppressive therapies [Hahn, 2013], but studies in 
some European countries have shown belimumab to be cost-effective in 
those medical settings [Specchia et al., 2014, Díaz-Cerezo et al., 2015, 
Pierotti et al., 2015]. An Italian study showed an Incremental Cost-
Effectiveness Ratio (ICER) value per life year gained of €22,990 and an 
incremental cost per Quality Adjusted Life Year (QALY) of €32,859 based 
on a belimumab price which includes a confidential patient access scheme 
(PAS) [Pierotti et al., 2015].  
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In the UK, the company developed a model to evaluate cost-effectiveness 
in this particular setting, which includes patient characteristics, disease 
activity, medication (corticosteroid use), risk of organ damage 
development and mortality. Data were gathered from the Johns Hopkins 
cohort, BLISS trials and other data from the literature. In this model, the 
incremental costs were £51,925, the incremental QALYs 0.806 and the 
ICER £64,410 per QALY gained. However, when this model is applied to a 
maximum treatment of 6 years (which is thought to be long enough to 
guarantee a reduction in long-term morbidity), it resulted in a lower ICER 
of £47,342 per QALY gained. A significant proportion of patients will 
probably need treatment for more than 6 years. Despite doubts about the 
economic modelling in the UK and a list price of £121.50 for a 120-mg vial 
and £405 for a 400-mg vial (the company agreed a PAS, providing a simple 
discount which is confidential), NICE finally decided to approve its use in 
restricted circumstances [NICE, 2016].  
 
4.  Clinical pearls 
 
Belimumab has been approved in the UK as an option in SLE patients with 
serologically active disease and a SELENA-SLEDAI score equal or greater 
than 10, as this constitutes a clinically relevant group of patients. The 
recommended dosage is 10 mg/kg on days 0, 14, 28, and subsequently 
every 28 days. Treatment should only be continued beyond 24 weeks if 
there is an improvement in the SELENA-SLEDAI score of at least 4 points 
[NICE, 2016], but an American study has showed that more than 50% of 
patients take it for >6 months [Hill et al., 2015]. Due to doubts regarding 
the use of SELENA-SLEDAI in clinical practice, it was decided not to use a 
more restricted SELENA-SLEDAI score improvement of >6. In the UK, it was 
also determined that evidence regarding Belimumab will be collected 
through the British Isles Lupus Assessment Group (BILAG) registry [NICE, 
2016]. 
However, there are still many unanswered questions as far as length of 
treatment is concerned. Some experts hypothesize that it might be 
stopped sometime after sustained response is achieved or on-demand, 
similarly to other treatments used in SLE. As previously discussed, 
belimumab seems to reduce the rate of flares over time [Ginzler et al., 
2014], but there are a few reports of severe flares after discontinuation 
[Furer et al., 2016]. 
Belimumab in SLE: evidence-to-date and clinical usefulness 
 
17 
 
5. What does the future hold? 
Several randomized control trials of belimumab are recruiting or ongoing 
at the moment. As the two original trials excluded patients with active 
lupus nephritis, the effect of belimumab in these patients is unknown A 
phase III clinical trial is evaluating its efficacy and safety in this subset 
(NCT01639339). Due to the differences between the BLISS trials, there are 
2 randomized controlled trials assessing clinical response and safety in 
black (NCT01632241) and East-Asian (NCT01345253) patients. A multi-
centre study in a paediatric population is also ongoing (NCT01649765). 
Belimumab might also have a role when used together with Rituximab 
(RTX), as BAFF seems to drive disease flare following RTX in patients with 
elevated anti-dsDNA titres and low B-cell numbers and sequential RTX 
may promote ever-increasing levels of BAFF [Carter et al., 2013]. A trial 
(Beat-Lupus) will determine whether belimumab can successfully be used 
following B-cell depletion with RTX to prevent further SLE flares in this 
subgroup of patients [Arthritis Research UK, 2015]. Two open label studies 
are currently recruiting: one comparing a combination of rituximab and 
cyclophosphamide with a combination of rituximab and 
cyclophosphamide followed by belimumab in the treatment of lupus 
nephritis (NCT02260934); the other investigating the possibility of 
combining RTX and belimumab (NCT02284984). A phase III trial to 
evaluate efficacy and safety of subcutaneous belimumab has just been 
completed (NCT01484496). 
In order to evaluate the effect of belimumab suspension for 6 months 
followed by its reintroduction, an open-label non-randomized study has 
also been commenced (NCT02119156). 
The BASE (NCT01705977) and the SABLE (NCT01729455) studies are 
evaluating long-term safety, especially serious events. A Pregnancy 
Register (NCT01532310) is assessing women who received belimumab 
within the 4 months prior to and/or during pregnancy. One study has 
recently been completed, considering the effect of belimumab in vaccine 
responses (NCT01597492). 
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6. Conclusion 
Belimumab is approved for treating patients with active, autoantibody 
positive SLE with a SELENA-SLEDAI ≥10, who do not respond to 
conventional therapies. The data from the clinical trials, post-hoc analyses 
and long term follow-up studies are reasonably reassuring and are 
reviewed in Table 1. Belimumab seems to have some modest benefit in 
improving disease activity without an increase in significant adverse 
effects. However, it does not induce rapid clinical benefit and we know 
very little about its effectiveness in treating patients with renal, CNS, heart 
or lung disease. Many unanswered questions about the subgroups of 
patients who might benefit the most or the possible combinations with 
other therapies remain.  
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Table 1. Pros and cons of belimumab treatment 
Pros Cons 
Moderate efficacy in serologically 
active patients with skin and joint 
involvement [Furie et al., 2011, 
Navarra et al., 2011] 
Improvement in immunological 
markers [Stohl et al., 2012] 
No safety issues or increased 
mortality [Ginzler et al., 2014, 
Bruce et al., 2016] 
Lack of data about benefit in CNS, 
renal, lung and heart involvement 
Slow onset of action [Hui-Yuen et 
al., 2015] 
Lack of data regarding safety in 
pregnancy [Wallace et al., 2013] 
Contradictory data on 
corticosteroid dose sparing [Hui-
Yuen et al., 2015, Collins et al., 
2016] 
No data on combination therapies 
CNS: Central Nervous System  
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Figure 1. Pros and cons of belimumab treatment 
CNS: Central Nervous System 
 
 
